Back to results
RecruitingPhase 2

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

NCT05759572

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Breast cancer institute of Fudan University Cancer Hospital

Shanghai, Shanghai Municipality, China

View on ClinicalTrials.gov
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer — TrialFind